Englewood Lab (950140) investor relations material

Executive summary

• Q2 2026 consolidated revenue was KRW 51.9 billion, down 9.7% year-over-year, with operating profit at KRW 8.7 billion, down 13.2% year-over-year.

• Net income for Q2 2026 was KRW 6.7 billion, a 5.2% decrease year-over-year.

• Operates as a cosmetics ODM/OEM manufacturer in the US, specializing in skincare and functional cosmetics, with a strong R&D focus and global certifications.

• Main revenue comes from moisturizers, face creams, and other basics, with significant export sales and a diversified customer base.

• The company is listed on KOSDAQ and is majority-owned by a strategic shareholder, with stable management and no significant legal or regulatory issues.

Financial highlights

• 12M 2025 consolidated revenue reached KRW 216.8 billion, up 19.0% YoY, with operating profit at KRW 37.4 billion, up 98.8% YoY.

• Consolidated revenue for H1 2026 was $68.5M, down from $152.4M for FY2025 and $133.6M for FY2024.

• Net income for FY2025 was KRW 24.8 billion, up 26.4% YoY.

• Operating income for H1 2026 was $9.6M, compared to $26.3M in FY2025 and $13.8M in FY2024.

• Cash and cash equivalents at June 30, 2026, were $29.0M.

Outlook and guidance

• Growth strategy focuses on expanding the U.S. skincare business, specializing in OTC cosmetics, and global market expansion through new product launches and increased production capacity.

• The company aims to expand in the premium skincare market and continue targeting global top-tier brands.

• Focus remains on R&D, regulatory compliance, and maintaining high quality and timely delivery.